Extract
Breathlessness is the most common and disabling symptom in patients with interstitial lung disease (ILD), significantly affecting their quality of life. Therefore, alleviating breathlessness is a primary focus in the symptom management of patients with ILD. However, therapeutic options for patients with ILD are limited [1]. Herein, we introduce a novel symptom-based treatment for breathlessness in patients with ILD.
Abstract
Olfactory stimulation with l-menthol may be a safe and effective treatment in patients with interstitial lung disease. It significantly decreases breathing discomfort, air hunger, and breathing effort during inspiratory resistive loaded breathing. https://bit.ly/40KQ0Ns
Footnotes
This clinical trial was prospectively registered with Japan Registry of Clinical Trials: jRCT1030220389. No data sharing provision has been made.
Conflict of interest: None declared.
Support statement: This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (21K11206, 18K17741, and 26870760), Research Grants from Osaka Gas Group Welfare Foundation (H28 and H29), Research Grant from Furukawa Medical and Welfare Foundation (H31), and a European Respiratory Society/European Lung Foundation travel grant for best abstract in patient-centred research.
- Received December 20, 2022.
- Accepted April 20, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
